Financial Survey: Theravance Biopharma (NASDAQ:TBPH) and Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN) and Theravance Biopharma (NASDAQ:TBPH) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Volatility & Risk

Urogen Pharma has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Urogen Pharma and Theravance Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1	1	8	0	2.70
Theravance Biopharma	0	8	0	0	2.00

Urogen Pharma presently has a consensus price target of $52.38, indicating a potential upside of 22.83%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 13.92%. Given Urogen Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe Urogen Pharma is more favorable than Theravance Biopharma.

Valuation and Earnings

This table compares Urogen Pharma and Theravance Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$188.73 million	11.04	-$153.49 million	($1.98)	-21.54
Theravance Biopharma	$104.31 million	8.48	$105.89 million	$1.01	16.86

Theravance Biopharma has lower revenue, but higher earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by company insiders. Comparatively, 7.6% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Urogen Pharma and Theravance Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Theravance Biopharma	51.58%	-0.77%	-0.46%

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

About Theravance Biopharma

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.